Jan. 13 at 4:46 PM
$OCUL Interesting Q&A from
$EYPT at JMP this morning....
"Just we know there's a competitor out there that has a study reading out shortly. The phase three soul one study. Can you can you maybe talk through J. Really what I'm interested in is, is what the read Through's are for your program from those data, from your perspective? "
". So sure. So at a high level, I think we already know this tkis work. There's been to my knowledge now eight TKI trials with various delivery systems, intra vitreal, orally suprachoroidal in wet AMD, and they've all been positive. And so I do expect this study to show a positive benefit of tkis. Beyond that, however, the study design again is very, very different than what we're doing. And given that retinal physicians don't typically watch patients lose 15 letters, it's hard to know how applicable that result will be in the real world. "
